Results compared to same quarter last year. Seems buyers arnt keen on this share as it seems to be heading in right direction. Need something to spark the fire as ots not on any radars.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling